BRPI0409632A - combinações antineoplásticas - Google Patents

combinações antineoplásticas

Info

Publication number
BRPI0409632A
BRPI0409632A BRPI0409632-0A BRPI0409632A BRPI0409632A BR PI0409632 A BRPI0409632 A BR PI0409632A BR PI0409632 A BRPI0409632 A BR PI0409632A BR PI0409632 A BRPI0409632 A BR PI0409632A
Authority
BR
Brazil
Prior art keywords
antineoplastic combinations
antineoplastic
combinations
cci
neoplasms
Prior art date
Application number
BRPI0409632-0A
Other languages
English (en)
Inventor
James J Gibbons Jr
Gary Dukart
Matthew L Sherman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0409632A publication Critical patent/BRPI0409632A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

"COMBINAçõES ANTINEOPLáSTICAS". A presente invenção refere-se ao uso de uma combinação de CCI-779 e interferon alfa (<244>) no tratamento de neoplasmas.
BRPI0409632-0A 2003-04-22 2004-04-14 combinações antineoplásticas BRPI0409632A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46449803P 2003-04-22 2003-04-22
PCT/US2004/011458 WO2004093854A2 (en) 2003-04-22 2004-04-14 Antineoplastic combinations

Publications (1)

Publication Number Publication Date
BRPI0409632A true BRPI0409632A (pt) 2006-04-25

Family

ID=33310901

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409632-0A BRPI0409632A (pt) 2003-04-22 2004-04-14 combinações antineoplásticas

Country Status (26)

Country Link
US (1) US20040258662A1 (pt)
EP (1) EP1615640B1 (pt)
JP (1) JP2006524246A (pt)
KR (1) KR20060006058A (pt)
CN (1) CN1777424A (pt)
AR (1) AR044039A1 (pt)
AT (1) ATE352301T1 (pt)
AU (1) AU2004231720A1 (pt)
BR (1) BRPI0409632A (pt)
CA (1) CA2519338A1 (pt)
CL (1) CL2004000836A1 (pt)
CO (1) CO5630033A2 (pt)
CR (1) CR7993A (pt)
DE (1) DE602004004520T2 (pt)
DK (1) DK1615640T3 (pt)
EC (1) ECSP056114A (pt)
ES (1) ES2279407T3 (pt)
MX (1) MXPA05010582A (pt)
NO (1) NO20054412L (pt)
PL (1) PL1615640T3 (pt)
PT (1) PT1615640E (pt)
RU (1) RU2005136222A (pt)
TW (1) TW200503753A (pt)
UA (1) UA80756C2 (pt)
WO (1) WO2004093854A2 (pt)
ZA (1) ZA200508574B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
CN101137748B (zh) 2005-03-07 2011-12-14 罗巴斯研究机构 粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用
KR101354828B1 (ko) * 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
US20070116757A1 (en) * 2005-11-08 2007-05-24 Collegium Pharmaceutical, Inc. Methylene Blue Derivatives
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
MX2011001318A (es) 2008-08-04 2011-03-04 Wyeth Llc Combinaciones antineoplasicas de 4-anilino-3-cianoquinolinas y capecitabina.
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
EP2416774B1 (en) 2009-04-06 2015-11-04 Wyeth LLC Treatment regimen utilizing neratinib for breast cancer
US9278090B2 (en) * 2012-09-05 2016-03-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preventing the development of mucositis and related disorders

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
DK1318837T3 (da) * 2000-08-11 2005-01-10 Wyeth Corp Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
ATE375166T1 (de) * 2002-06-07 2007-10-15 Waratah Pharmaceuticals Inc Zusammensetzungen und verfahren zur behandlung von diabetes
BR0314397A (pt) * 2002-09-17 2005-08-09 Wyeth Corp Formulações orais

Also Published As

Publication number Publication date
RU2005136222A (ru) 2006-03-20
ES2279407T3 (es) 2007-08-16
PL1615640T3 (pl) 2007-05-31
CO5630033A2 (es) 2006-04-28
DE602004004520D1 (de) 2007-03-15
JP2006524246A (ja) 2006-10-26
AU2004231720A1 (en) 2004-11-04
AR044039A1 (es) 2005-08-24
MXPA05010582A (es) 2005-11-23
CA2519338A1 (en) 2004-11-04
NO20054412L (no) 2005-11-21
ECSP056114A (es) 2006-03-01
UA80756C2 (en) 2007-10-25
WO2004093854A2 (en) 2004-11-04
EP1615640A2 (en) 2006-01-18
ZA200508574B (en) 2007-04-25
DE602004004520T2 (de) 2007-11-08
US20040258662A1 (en) 2004-12-23
HK1081463A1 (en) 2006-05-19
DK1615640T3 (da) 2007-03-12
PT1615640E (pt) 2007-04-30
EP1615640B1 (en) 2007-01-24
NO20054412D0 (no) 2005-09-23
KR20060006058A (ko) 2006-01-18
WO2004093854A3 (en) 2005-02-03
TW200503753A (en) 2005-02-01
CL2004000836A1 (es) 2005-03-04
ATE352301T1 (de) 2007-02-15
CN1777424A (zh) 2006-05-24
CR7993A (es) 2006-05-26

Similar Documents

Publication Publication Date Title
BRPI0409632A (pt) combinações antineoplásticas
BR0211769A (pt) Combinações antineoplásicas
CY1108109T1 (el) Χρηση cci-779 ως αντινεοπλασματικου παραγοντα
DE69907977D1 (de) Pyrrolobenzodiazepine
FR2836297B1 (fr) Bougie d&#39;allumage
SG152279A1 (en) Interfering rna duplex having blunt-ends and 3æ-modifications
BRPI0317545A2 (pt) &#34;composições de poli-hema de baixa polidispersão&#34;
BRPI0411528A (pt) uso de isomalte como prebiótico
ATE341537T1 (de) Dolastatin 10 derivate
DE60216254D1 (de) Acrylkautschukzusammensetzung und vulkanisat
BR0306905A (pt) Vacinas de flavivìrus
DE60115126D1 (de) Funduskamera mit sichtbarer und unsichtbarer Beleuchtung
EP1628375A4 (en) SPARK PLUG
EP1708326A4 (en) SPARK PLUG
BR0210101A (pt) Combinações antineoplásticas
BR0014560B1 (pt) uso de uma composiÇço de tratamento de tecidos.
DE60334012D1 (de) Valerolactonverbindungen und parf mzusammensetzung
DE60318590D1 (de) Vernetzbare acrylkautschukzusammensetzung und formkörper
EG23929A (en) Isoxazolines derivatives and their use as antidepressants
SM200300009B (it) Composizione e suo uso terapeutico
SE0302485L (sv) Novel copolymer and cement additive comprising the same
FR2843244B1 (fr) Bougie d&#39;allumage
DE60216370D1 (de) Kraftstoffzusatz und denselben enthaltende Kraftstoffzusammensetzung
FR2791258B1 (fr) Composition amincissante
EP1416945A4 (en) IMPROVED HETEROPOLYMER COMPLEXES AND METHOD FOR THEIR USE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.